Pharmacologic Inhibition of YAP/TEAD and Development of New Chorioretinal Atrophy

Is pharmacologic inhibition of the Hippo pathway associated with chorioretinal changes similar to those seen in inherited disorders caused by Hippo pathway mutations?In this case report, a patient treated with a yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD) inhibitor, a transcription complex downstream of the Hippo pathway, developed chorioretinal findings mimicking those seen in helicoid peripapillary chorioretinal degeneration, an inherited disease caused by loss-of-function mutations in .Pharmacologic inhibition of YAP/TEAD was associated with development of new chorioretinal atrophy; patients taking YAP/TEAD inhibitors or other drugs targeting the Hippo pathway should undergo ophthalmologic monitoring.

Corresponding Author: Dean Eliott, MD, Department of Ophthalmology, Mass Eye and Ear, Harvard Medical School, 243 Charles St, Boston, MA 02114 (dean_eliott@meei.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.